Clinical Trial Update: Autologous Adipose-derived Stromal Vascular Fraction for Treatment of Post COVID-19 [NA]

View source ↗

Summary

A clinical trial evaluating autologous adipose-derived stromal vascular fraction for post-COVID-19 was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• Autologous adipose-derived stromal vascular fraction

Snippet

Sponsor: GID BIO, Inc. | Conditions: Covid19 | NA | Status: WITHDRAWN